Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
← catalyst calendarSponsored by Fulcrum Therapeutics (industry) · FULC — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
45actual
Sites
18
Countries
Nigeria, South Africa, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-13 | actual | When the study began enrolling |
| Primary completion | 2026-01-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-20 | actual | The whole study's end, after follow-up |
| First posted | 2021-12-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sickle Cell Disease
- Sickle Cell Anemia
Intervention
- Drug: Pociredir oral capsule(s) — also filed as FTX-6058
Primary outcomes
what the primary-completion date above is the date OFTreatment-Emergent Adverse Events
measured Up to approximately 16 weeks of monitoring
Plasma Concentrations of Pociredir
measured Days 1, 14, 28, 42, 56, 70, 84 and 91
Publications
- PMID 22017641 — cited as background
- PMID 28423290 — cited as background
- PMID 23209159 — cited as background
- PMID 24361300 — cited as background
- PMID 24222332 — cited as background
- PMID 40569673 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · FULC's whole pipeline · Catalyst calendar · Every registered study · What changed